Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ligand Pharmaceuticals Incorporated before investing.

In this article, we go over a few key elements for understanding Ligand Pharmaceuticals Incorporated’s stock price such as:

• Ligand Pharmaceuticals Incorporated’s current stock price and volume
• Why Ligand Pharmaceuticals Incorporated’s stock price changed recently
• Upgrades and downgrades for LGND from analysts
• LGND’s stock price momentum as measured by its relative strength

About Ligand Pharmaceuticals Incorporated (LGND)

Before we jump into Ligand Pharmaceuticals Incorporated’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Want to learn more about Ligand Pharmaceuticals Incorporated’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ligand Pharmaceuticals Incorporated.

Ligand Pharmaceuticals Incorporated’s Stock Price as of Market Close

As of July 29, 2026, 4:00 PM, CST, Ligand Pharmaceuticals Incorporated’s stock price was $288.010.

Ligand Pharmaceuticals Incorporated is down 2.79% from its previous closing price of $296.280.

During the last market session, Ligand Pharmaceuticals Incorporated’s stock traded between $287.190 and $298.290. Currently, there are approximately 19.88 million shares outstanding for Ligand Pharmaceuticals Incorporated.

Ligand Pharmaceuticals Incorporated’s price-earnings (P/E) ratio is currently at 38.4, which is high compared to the Pharmaceuticals industry median of 21. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Ligand Pharmaceuticals Incorporated Stock Price History

Ligand Pharmaceuticals Incorporated’s (LGND) price is currently down 8.88% so far this month.

During the month of July, Ligand Pharmaceuticals Incorporated’s stock price has reached a high of $326.630 and a low of $287.190.

Over the last year, Ligand Pharmaceuticals Incorporated has hit prices as high as $326.630 and as low as $129.550. Year to date, Ligand Pharmaceuticals Incorporated’s stock is up 52.33%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ligand Pharmaceuticals Incorporated Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 29, 2026, there were 0 analysts who downgraded Ligand Pharmaceuticals Incorporated’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Ligand Pharmaceuticals Incorporated’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ligand Pharmaceuticals Incorporated’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Ligand Pharmaceuticals Incorporated’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ligand Pharmaceuticals Incorporated (LGND) by visiting AAII Stock Evaluator.

Relative Price Strength of Ligand Pharmaceuticals Incorporated

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 29, 2026, Ligand Pharmaceuticals Incorporated has a weighted four-quarter relative price strength of 19.57%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Ligand Pharmaceuticals Incorporated is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ligand Pharmaceuticals Incorporated Stock Price: Bottom Line

As of July 29, 2026, Ligand Pharmaceuticals Incorporated’s stock price is $288.010, which is down 2.79% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ligand Pharmaceuticals Incorporated stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.